Antibody-Drug Conjugates in Uro-Oncology.
Currently available treatment options for patients with refractory metastatic prostate, bladder, or kidney cancers are limited with the prognosis remaining poor. Advances in the pathobiology of tumors has led to the discovery of cancer antigens that may be used as the target for cancer treatment. An...
| Publicado en: | Targeted Oncology Vol. 17; no. 3; pp. 203 - 222 |
|---|---|
| Autores principales: | , , , |
| Formato: | research Journal Article |
| Publicado: |
Springer Nature
May2022
|
| Acceso en línea: | Ver este registro en EBSCOhost |